Clinical Trials on Pure Red-Cell Aplasia

Total 3894 results

Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant

Multiple Myeloma and Plasma Cell Neoplasm

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Riverside Haematology Group

Unknown

Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
Oncotherapeutics

Completed

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
The Cleveland Clinic

Completed

Rituximab in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Tennessee

Completed

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Multiple Myeloma and Plasma Cell Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Completed

Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic
National Cancer Institute (NCI)

Completed

High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse

Multiple Myeloma and Plasma Cell Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma

United States
NCIC Clinical Trials Group

Completed

Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Canada
University of Southampton
NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation... and other collaborators

Terminated

High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant (AntiCD-66)

Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
CTI BioPharma

Terminated

Arsenic Trioxide in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
NCIC Clinical Trials Group

Completed

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Canada, United States
University of Maryland, Baltimore
National Cancer Institute (NCI); University of Maryland Greenebaum Cancer Center

Completed

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Maryland, Baltimore

Completed

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Roswell Park Cancer Institute

Completed

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Medical Research Council

Unknown

Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
Oncotherapeutics

Unknown

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Oncotherapeutics

Completed

Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Erasme University Hospital

Unknown

High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Belgium, Poland
Leeds Cancer Centre at St. James's University Hospital

Unknown

High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy

Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
The Cleveland Clinic

Completed

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
California Cancer Consortium
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
AEterna Zentaris

Completed

AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Canada
Mayo Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm
Institut Paoli-Calmettes

Completed

Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment

Multiple Myeloma and Plasma Cell Neoplasm

France
Mayo Clinic
National Cancer Institute (NCI)

Completed

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of California, San Francisco
National Cancer Institute (NCI)

Unknown

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Lymphoma | Kidney Cancer | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Hoag Memorial Hospital Presbyterian
Cancer Biotherapy Research Group

Withdrawn

Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy

Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Siriraj Hospital

Not yet recruiting

Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing (genetics MM)

Plasma Cell Disorder
Senesco Technologies, Inc.

Unknown

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Multiple Myeloma | Plasma Cell Leukemia | Multiple Myeloma in Relapse | Mantle Cell Lymphoma in Relapse | Diffuse Large B Cell Lymphoma in Relapse | Other B Cell Lymphoma in Relapse

United States, South Africa
Sanofi

Recruiting

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM (IRAKLIA)

Plasma Cell Myeloma Recurrent

United States, Argentina, Australia, Brazil, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Italy, Japan, Norway, Poland, Spain, Sweden, Taiwan, Turkey, United Kingdom

Clinical Trials on Pure Red-Cell Aplasia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations